Oncoteq is a clinical stage oncology biotech focused on drug development powered by AI.
Headquartered in Cham, Switzerland, with a focus on innovative treatments for cancer, the company pipeline currently comprises three assets of first-in-class or best-in-class innovative therapeutic options in areas of high unmet need.
What we do
Oncoteq is a clinical stage biotechnology company focused on drug development within oncology.
Oncoteq leverages artificial intelligence to identify the optimal applications of a given molecule and de-risk clinical development.
Oncoteq est.
2022
Privately held
10+ Employees
Strategic partners
Innoplexus
Office in Cham
Founded, seeded by Cureteq AG
Latest news
New TEQ102 publication
We are very pleased that the convincing data on Oncoteq’s #TEQ102, former TUB-010, by partner and inventor, Tubulis GmbH, has been published. Please check it out and don’t hesitate to reac …
Oncoteq is attending Bio€quity Europe 2025, Bruges, Belgium, between 12-14 May
Please reach out to CEO Mads Dalsgaard for meetings or networking
Shortcuts
About Us
Oncoteq is a clinical stage biotech, that leverages AI to unlock the value of exciting oncology assets
Pipeline
The Oncoteq pipeline currently comprises three assets focusing on oncology. Oncoteq
Platform
The Cureteq platform uniquely combines a fully flexible and agile biotech company-builder model with AI supported drug development
Transforming drug development
We aim to transform drug development and drive assets beyond value inflection points by:
- Unlocking hidden value of unattended molecules through AI
- Combining agility and expertise in a lean structure
- Flexibly partnering and financing assets